[The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection].

Abstract

OBJECTIVE:

To evaluate the clinical efficacy and safety of intravenous panipenem-betamipron in the treatment of moderate to severe pulmonary infection.

METHODS:

An open, perspective, multicenter clinical trial was conducted. Among the enrolled 665 patients, 621 patients with moderate to severe pulmonary infection were treated with intravenous panipenem-betamipron at a dose of 500 mg every 6 hours per day for 7 - 14 days. Among them, the community acquired pneumonia (CAP), hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) patients were 55.6% (345/621), 37.0% (230/621) and 7.4% (46/621), respectively. All the adverse events were recorded.

RESULTS:

The overall effective rate of panipenem-betamipron was 84.4% with CAP of 91.9%, HAP of 76.1% and VAP of 69.6%. The effective rates in the patients with moderate and severe pulmonary infection were 87.5% and 82.8%, respectively. Bacterial separation rate was 54.8% and bacterial eradication rate was 80.9%. Bacterial eradication rates to pseudomonas aeruginosa, pneumobacillus, Escherichia coli. and acinetobacter baumannii were 74.7%, 95.6%, 89.5% and 50.9%, respectively. The adverse events rate was 1.8% (12/665).

CONCLUSION:

Intravenous panipenem-betamipron is effective in treating moderate to severe pulmonary infection with low adverse events rate.

• Authors: Clinical Trial Research Group on Panipenem-betamipron
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 51 Issue 7 Pg. 547-50 (Jul 2012) ISSN: 0578-1426 [Print] China
• PMID: 22943829 (Publication Type: English Abstract, Journal Article, Multicenter Study)

Chemical References

• Anti-Bacterial Agents
• Thienamycins
• beta-Alanine
• panipenem-betamipron

Topics

• Adult
• Aged
• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Community-Acquired Infections (drug therapy)
• Cross Infection (drug therapy)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Pneumonia, Bacterial (drug therapy)
• Prospective Studies
• Thienamycins (adverse effects, therapeutic use)
• Treatment Outcome
• beta-Alanine (adverse effects, analogs & derivatives, therapeutic use)